Search PubMed⌕ Search

Biomedical subjects

S Tyano

Publications and source records attributed to S Tyano.

At least 91 records · Page 5Linked to original sources
PubMed1988

Up-regulatory effect of triphasic oral contraceptive on platelet 3H-imipramine binding sites.

Triphasic oral contraceptive (Logynon) induced a significant increase (36%) in the maximal binding capacity of platelet membranes for [3H]imipramine. The increase was achieved in the second Logynon cycle as compared to pretreatment and first Logynon cycle binding values. The pill contains a combination of ethinyl estradiol and levonorgestrel, and it is as yet unclear which of the two hormones is responsible for the up-regulatory effect. The increase in the density of platelet imipramine binding sites may reflect a similar alteration in brain. The increase in imipramine binding did not correlate with alteration in mood as assessed by Beck Depression Inventory scores.

Adult↗
PubMed1988

Obsessive compulsive disorders in adolescence.

This article reports our experience with 14 adolescent cases of Obsessive Compulsive Disorder (OCD). In contradistinction to other reports in the literature, our results were quite good with these patients. Although we used recommended treatment measures (exposure in vivo and clomipramine drug therapy), we found a good prognosis to be independent to these specific measures. In fact, adolescents tend not to cooperate very well with behaviour therapy and medication. Psychotherapy, on the other hand, was often quite useful. Our conclusion is that non-specific milieu therapy leads to recovery in a majority of adolescent obsessive compulsives. We are not sure as to how long these remissions will last on follow-up.

Adolescent↗
PubMed1988

Psychopathology and management of hospitalized Ethiopian immigrant adolescents in Israel.

Over a period of about 12 months a large number of Ethiopian Jews emigrated to Israel under very stressful conditions. Many of these immigrants were adolescents who came on their own, leaving their families behind. Despite the culture shock involved, most have done well. Nine of these youngsters, who developed psychiatric disabilities severe enough to warrant hospitalization, were referred to us. In this paper we describe the clinical and management problems posed by these patients.

Acculturation↗
PubMed1988

Plasma cortisol, prolactin, growth hormone, and immunoreactive beta-endorphin response to fenfluramine challenge in depressed patients.

The effect of a single dose (60 mg p.o.) of the serotonin agonistic agent fenfluramine (FNF) on plasma cortisol, prolactin (PRL), growth hormone (GH), and immunoreactive beta-endorphin (ir-beta-EP) levels was assessed in eight major depressed patients and eight controls. The hormones were monitored at basal level (0') and hourly during 5 h following FNF administration. The pharmacological challenge caused an elevation of 80% in PRL secretion in the healthy controls and only 42% in the depressed patients. However, the actual prolactin response (delta max) failed to discriminate depressed patients from controls. A blunted response followed by a decrease (33%) in serum cortisol levels was observed in depressed patients 5 h after drug administration while an increase of 94% was obtained in controls after 3 h. FNF provocation did not affect GH and ir-beta-EP plasma levels. The blunted cortisol responsiveness to FNF administration in depressed patients may reflect functional hypoactivity of central serotonergic system at least during the acute phase of major depression. It is not clear why the cortisol hyporesponsivity in depressed patients is not accompanied by a similar reduced PRL response to FNF challenge.

Adult↗
PubMed1988

Psychopathology and temporal lobe epilepsy in adolescents.

Although high rates of psychopathology in children and adolescents suffering from temporal lobe epilepsy (TLE) have been reported in the literature, the subject remains controversial. In this investigation we made a psychiatric study of 26 adolescents with TLE using a detailed structure interview and rigorous diagnostic criteria. These were compared to 26 matched controls suffering from chronic bronchial asthma (BA). In neither group was there a high rate of specific psychiatric illness, although many adolescents in both samples showed moderate to severe depression. We conclude that TLE may not be a specific cause of psychopathology in adolescence, and that the depression might result from the suffering involved in chronic illness.

Adjustment Disorders↗
PubMed1988

Use of the Child Behavior Checklist in an Israeli adolescent psychiatric unit.

This article deals with the Hebrew version of an instrument for the diagnosis of psychopathology in young adolescents: the Child Behavior Checklist and the associated Child Behavior Profile developed by Achenbach (1978). We report on a study of the reliability and validity of the checklist and its suitability for use with severely disturbed adolescents in Israel. Parents of 130 adolescents, 89 healthy and 41 sick, participated in the research. The scales were found to be valid in that two-thirds of the items were correctly assigned by clinicians in Israel to their respective scales; it is internally consistent as measured by the Cronbach coefficient; and it is reliable in distinguishing between patient and control groups. Scores for control adolescents in Israel were found to be very similar to norms in the United States, the Netherlands and Chile. This finding may have important implications for cross-cultural research.

Adolescent↗
PubMed1988

Unaltered platelet [3H]-imipramine binding in dementia of the Alzheimer type.

High-affinity [3H]-imipramine binding to platelets was evaluated in 11 patients suffering from dementia of Alzheimer type (DAT) in comparison to 12 normal controls. The [3H]-imipramine binding values (Bmax and Kd) did not differ between the DAT patients and the controls. Previous studies have demonstrated hypofunction of central serotonergic system in this disease, including reduced imipramine binding to brain. Thus, it seems that the low imipramine binding in DAT is confined to the brain tissue and not reflected in the platelets.

Aged↗
PubMed1988

Kinetic values of active serotonin transport by platelets of bipolar, unipolar and schizophrenic patients at 2 and at 8 a.m. Preliminary report.

Serotonin active transport by platelets of psychiatric patients was determined at 2 and at 8 a.m. Kinetic values, Vmax and Km, of serotonin uptake by platelets of bipolar depressive patients at 2 a.m. were higher than those at 8 a.m. Contrary to that, the kinetic values, Vmax and Km, for unipolar patients at 2 a.m. were rather lower than the values at 8 a.m. Serotonin uptake kinetics by platelets of schizophrenic patients at 2 a.m. were similar to those at 8 a.m. The curves of serotonin uptake kinetics by platelets of bipolar patients at 2 and at 8 a.m. were different from those observed for platelets of unipolar and schizophrenic patients. The variability of the kinetics of serotonin uptake by platelets of the three groups of psychiatric patients may offer a clue to the heterogenicity of these disorders.

Aged↗
PubMed1988

Cold agglutinin titers in psychiatric patients.

Cold agglutinin titers were obtained from the serum of 41 psychiatric patients. The 21 chronic schizophrenic patients tended to have positive cold agglutinin titers; the authors suggest that this immunological finding may be associated with long-term neuroleptic treatment.

Adult↗
PubMed1987

Carbamazepine up-regulates the binding of [3H]PK 11195 to platelets of epileptic patients.

The maximal number of binding sites (Bmax) and the equilibrium dissociation constant (KD) values for [3H]PK 11195 binding were determined in the platelet membranes of epileptic patients before and after 4 weeks of carbamazepine (CBZ) treatment, as well as in healthy controls. There was a decrease of 17.1% in the Bmax value of patients before treatment as compared to the controls whereas an increase of 50.3% was observed in CBZ-treated patients as compared to their pretreatment values. The up-regulatory effect of CBZ on peripheral benzodiazepine receptors was not accompanied by alterations in KD values.

Adolescent↗
PubMed1987

Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients.

Reduced (24%) [3H]PK 11195 binding capacity to platelet membranes was observed in anxious patients in comparison to age- and sex-matched normal controls. Four weeks of diazepam treatment induced elevation (69%) in the maximal number of binding sites, and 1 week of drug withdrawal resulted in a slight decrease (16%) in 'peripheral' benzodiazepine binding sites as compared to their level during treatment.

Adult↗
PubMed1987

Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity.

The effect of 5 mg/p.o. methylphenidate (MPH) challenge on beta-endorphin (beta-EP), growth hormone (GH), prolactin (Prl) and cortisol was investigated in 16 children suffering from attention deficit disorder with hyperactivity (ADDH) before and after 4 weeks MPH treatment. The study population consisted of 13 males and 3 females aged 6-11 years. All patients were drug free for at least 3 months prior to investigation. The severity of ADDH symptomatology and response to MPH chronic treatment was assessed using parent/teacher abbreviated Conners rating scale. Blood samples for beta-EP, cortisol, Prl and GH were drawn before initiation of treatment (basal pre-treatment level), 2 hours after MPH challenge, 4 weeks after MPH treatment (basal post-treatment level) and 2 hours after re-challenge with MPH. Chronic MPH treatment resulted in a decrease in basal Prl levels (5.5 +/- 2.8 vs 3.7 +/- 1.9 ng/ml; p less than 0.05). Pre-treatment challenge stimulates significantly both beta-EP (15.0 +/- 7.5 vs 12.5 +/- 5.3 pmol/l; p less than 0.05) and cortisol secretion (20.6 +/- 6.6 vs 12.6 +/- 5.8 micrograms/dl; p less than 0.05), and suppressed Prl secretion (4.0 +/- 1.5 vs 5.5 +/- 2.8 ng/ml; p less than 0.05). Re-challenge with MPH enhanced beta-EP levels (14.9 +/- 8.6 vs 10.6 +/- 5.0 pmol/l; p less than 0.05) but failed to affect cortisol, Prl and GH secretion. The acute and chronic neuroendocrine effects of MPH administration might be related to its dopaminergic and adrenergic agonistic activity. It might be that the stimulatory effect of single and repeated acute MPH administration on beta-EP release contributes to the beneficial effect of MPH treatment in ADDH children.

Attention Deficit Disorder with Hyperactivity↗
PubMed1987

Platelet [3H]imipramine binding in autism and schizophrenia.

[3H]Imipramine binding to platelet membranes was evaluated in ten autistics, eight schizophrenics and seven normal controls. The schizophrenics and eight out of the ten autistics were maintained on chronic neuroleptic treatment. Diagnosis of autism and schizophrenia was established according to the DSM-III criteria. No significant difference in the maximal binding capacity of [3H]imipramine (Bmax) and Kd values could be found among the three groups. It seems that the imipramine binding site is intact both in autism and schizophrenia.

Adolescent↗
PubMed1987

The effect of acute and repeated electroconvulsive treatment on plasma beta-endorphin, growth hormone, prolactin and cortisol secretion in depressed patients.

The effects of single and repeated electroconvulsive treatment (ECT) on beta-endorphin (beta-EP), cortisol, growth hormone (GH) and prolactin (Prl) plasma levels were investigated in nine depressed patients. Blood samples were monitored a day before ECT, the day of the first and sixth ECT (0, 30, 60 and 90 min after seizures), the day afterwards and 4 weeks after termination of the ECT course. A significant elevation of beta-EP levels was achieved immediately with and 24 h after the first and the sixth ECT. A transient increase in basal beta-EP was observed 1 day following the sixth ECT in comparison with pre-treatment level. Peak and 30 min levels of cortisol were increased compared with baseline by the first ECT. The former (peak) but not the latter (30 min) were increased also at the sixth treatment. GH levels were decreased the day after the first ECT in comparison with the pre-treatment levels and immediately following each ECT in comparison with baseline. A trend toward elevation of Prl was observed immediately after the first and sixth ECT, although the rise did not reach significant levels. ECT administration stimulated beta-EP and cortisol secretion and suppressed human GH release, possibly by activation of endorphinergic and/or serotonergic systems. These mechanisms might be involved in the beneficial effect of ECT in depression.

Adult↗